David Michael Johnson - Insider Trading Tracker

Aura Biosciences, Inc.

US ˙ NasdaqGM ˙ US05153U1079

Introduction

This page provides a comprehensive analysis of the known insider trading history of David Michael Johnson. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders

Companies with Reported Insider Positions

The SEC filings indicate David Michael Johnson has reported holdings or trades in the following companies:

Security	Title	Latest Reported Holdings
US:AURA / Aura Biosciences, Inc.	Director	179,167
US:ZNTL / Zentalis Pharmaceuticals, Inc.	Director	250,421

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David Michael Johnson. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases AURA / Aura Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in AURA / Aura Biosciences, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2025-05-16	AURA	Johnson David Michael	20,000	4.9000	20,000	4.9000	98,000	70	7.2300	46,600	47.55
2023-11-08	AURA	Johnson David Michael	9,601	7.3000	9,601	7.3000	70,087
2023-11-08	AURA	Johnson David Michael	10,000	7.3000	10,000	7.3000	73,000
2023-11-08	AURA	Johnson David Michael	10,000	7.3000	10,000	7.3000	73,000
2023-11-07	AURA	Johnson David Michael	76,000	7.1700	76,000	7.1700	544,920
2023-11-07	AURA	Johnson David Michael	47,000	7.1700	47,000	7.1700	336,990
2023-11-07	AURA	Johnson David Michael	47,000	7.1700	47,000	7.1700	336,990
2023-10-04	AURA	Johnson David Michael	6,566	8.6068	6,566	8.6068	56,512
2023-10-03	AURA	Johnson David Michael	13,500	8.2713	13,500	8.2713	111,663
2023-01-06	AURA	Johnson David Michael	700	10.5000	700	10.5000	7,350
2023-01-06	AURA	Johnson David Michael	904	10.5100	904	10.5100	9,501
2023-01-05	AURA	Johnson David Michael	300	10.0000	300	10.0000	3,000
2023-01-05	AURA	Johnson David Michael	96	10.0000	96	10.0000	960
2022-12-28	AURA	Johnson David Michael	2,000	9.7500	2,000	9.7500	19,500
2022-12-28	AURA	Johnson David Michael	2,000	9.7500	2,000	9.7500	19,500
2022-12-01	AURA	Johnson David Michael	5,000	12.3700	5,000	12.3700	61,850
2022-12-01	AURA	Johnson David Michael	5,000	12.3700	5,000	12.3700	61,850
2022-06-13	AURA	Johnson David Michael	7,000	13.9900	7,000	13.9900	97,930
2022-06-13	AURA	Johnson David Michael	7,000	13.9900	7,000	13.9900	97,930
2022-06-13	AURA	Johnson David Michael	20,000	13.9900	20,000	13.9900	279,800
2022-06-10	AURA	Johnson David Michael	3,000	15.0400	3,000	15.0400	45,120
2022-06-10	AURA	Johnson David Michael	3,000	15.0400	3,000	15.0400	45,120
2022-06-10	AURA	Johnson David Michael	10,000	15.0400	10,000	15.0400	150,400

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AURA / Aura Biosciences, Inc. Insider Trades

Insider Sales AURA / Aura Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in AURA / Aura Biosciences, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Purchases ZNTL / Zentalis Pharmaceuticals, Inc. - Short Term Profit Analysis

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2023-11-10	ZNTL	Johnson David Michael	17,000	9.8790	17,000	9.8790	167,943	59	16.4900	112,387	66.92
2020-04-07	ZNTL	Johnson David Michael	4,000	18.0000	4,000	18.0000	72,000

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ZNTL / Zentalis Pharmaceuticals, Inc. Insider Trades

Insider Sales ZNTL / Zentalis Pharmaceuticals, Inc. - Short Term Loss Analysis

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Min	Price at Min	Max Loss Avoided ($)	Max Loss Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

Insider Trading History

This table shows the complete list of insider trades made by David Michael Johnson as disclosed to the Securities Exchange Commission (SEC).

File Date	Tran Date	Form	Ticker	Security	Code	10b5-1	Shares	Remaining Shares	Percent Change	Share Price	Tran Value	Remaining Value
2025-06-18	2025-06-17	4	AURA	Aura Biosciences, Inc. Common Stock	A - Award		13,000	179,167	7.82
2025-06-18	2025-06-17	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	A - Award		57,603	250,421	29.87
2025-05-20	2025-05-16	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		20,000	166,167	13.68	4.90	98,000	814,218
2024-06-24	2024-06-20	4	AURA	Aura Biosciences, Inc. Common Stock	A - Award		10,500	146,167	7.74
2024-06-21	2024-06-21	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	A - Award		48,429	192,818	33.54
2023-11-13	2023-11-10	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	P - Purchase		17,000	144,389	13.34	9.88	167,943	1,426,419
2023-11-09	2023-11-08	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		10,000	75,000	15.38	7.30	73,000	547,500
2023-11-09	2023-11-08	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		10,000	75,000	15.38	7.30	73,000	547,500
2023-11-09	2023-11-08	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		9,601	135,667	7.62	7.30	70,087	990,369
2023-11-09	2023-11-07	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		47,000	65,000	261.11	7.17	336,990	466,050
2023-11-09	2023-11-07	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		47,000	65,000	261.11	7.17	336,990	466,050
2023-11-09	2023-11-07	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		76,000	126,066	151.80	7.17	544,920	903,893
2023-10-05	2023-10-04	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		6,566	50,066	15.09	8.61	56,512	430,908
2023-10-05	2023-10-03	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		13,500	43,500	45.00	8.27	111,663	359,802
2023-06-16	2023-06-16	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	A - Award		19,059	127,389	17.59
2023-01-09	2023-01-06	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		904	18,000	5.29	10.51	9,501	189,180
2023-01-09	2023-01-06	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		700	18,000	4.05	10.50	7,350	189,000
2023-01-09	2023-01-05	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		96	17,096	0.56	10.00	960	170,960
2023-01-09	2023-01-05	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		300	17,300	1.76	10.00	3,000	173,000
2022-12-30	2022-12-28	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		2,000	17,000	13.33	9.75	19,500	165,750
2022-12-30	2022-12-28	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		2,000	17,000	13.33	9.75	19,500	165,750
2022-12-15	2022-12-01	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		5,000	15,000	50.00	12.37	61,850	185,550
2022-12-15	2022-12-01	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		5,000	15,000	50.00	12.37	61,850	185,550
2022-06-14	2022-06-13	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		20,000	30,000	200.00	13.99	279,800	419,700
2022-06-14	2022-06-13	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		7,000	10,000	233.33	13.99	97,930	139,900
2022-06-14	2022-06-13	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		7,000	10,000	233.33	13.99	97,930	139,900
2022-06-14	2022-06-10	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		10,000	10,000		15.04	150,400	150,400
2022-06-14	2022-06-10	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		3,000	3,000		15.04	45,120	45,120
2022-06-14	2022-06-10	4	AURA	Aura Biosciences, Inc. Common Stock	P - Purchase		3,000	3,000		15.04	45,120	45,120
2022-06-10	2022-06-08	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	A - Award		24,871	108,330	29.80
2021-12-17	2021-06-04	4/A	ZNTL	Zentalis Pharmaceuticals, Inc. Stock Option (Right to Buy)	A - Award		22,500	22,500
2021-12-17	2021-06-04	4/A	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	A - Award		7,500	96,355	8.44
2021-11-02	2021-11-02	4	AURA	Aura Biosciences, Inc. Series E Convertible Preferred Stock	C - Conversion		-139,672	0	-100.00
2021-11-02	2021-11-02	4	AURA	Aura Biosciences, Inc. Common Stock	C - Conversion		139,672	139,672
2021-10-29	2021-10-28	4	AURA	Aura Biosciences, Inc. Stock Option (Right to Buy)	A - Award		24,000	24,000
2021-10-04	2021-10-04	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	S - Sale	X	-100	80,959	-0.12	67.20	-6,720	5,440,445
2021-10-04	2021-10-04	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	S - Sale	X	-7,904	81,059	-8.88	66.58	-526,240	5,396,827
2021-10-04	2021-10-04	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	S - Sale	X	-4,892	88,963	-5.21	65.95	-322,628	5,867,119
2021-06-08	2021-06-04	4	ZNTL	Zentalis Pharmaceuticals, Inc. Stock Option (Right to Buy)	A - Award		15,000	15,000
2021-06-08	2021-06-04	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	A - Award		5,000	93,855	5.63
2021-04-05	2021-04-05	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	S - Sale	X	-12,897	88,855	-12.67	43.50	-561,021	3,865,201
2020-12-03	2020-12-02	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	S - Sale	X	-2,825	101,752	-2.70	52.72	-148,934	5,364,365
2020-12-03	2020-12-02	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	S - Sale	X	-4,603	104,577	-4.22	51.61	-237,561	5,397,219
2020-12-03	2020-12-02	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	S - Sale	X	-3,868	109,180	-3.42	50.82	-196,572	5,548,528
2020-12-03	2020-12-02	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	S - Sale	X	-1,600	113,048	-1.40	49.80	-79,680	5,629,790
2020-12-03	2020-04-07	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	P - Purchase		4,000	114,648	3.62	18.00	72,000	2,063,664
2020-04-09	2020-04-07	4	ZNTL	Zentalis Pharmaceuticals, Inc. Common Stock	A - Award		51,587	110,648	87.35
2020-04-03		3	ZNTL	Zentalis Pharmaceuticals, LLC Common Stock				118,122
2020-04-03		3	ZNTL	Zentalis Pharmaceuticals, LLC Common Stock				118,122
2020-04-03		3	ZNTL	Zentalis Pharmaceuticals, LLC Common Stock				118,122

Open market or private purchase of non-derivative or derivative security

Open market or private sale of non-derivative or derivative security

Grant, award, or other acquisition of securities from the company (such as an option)

Conversion of derivative

Sale or transfer of securities back to the company

Payment of exercise price or tax liability using portion of securities received from the company

Gift of securities by or to the insider

Equity swaps and similar hedging transactions

Exercise or conversion of derivative security received from the company (such as an option)

A transaction voluntarily reported on Form 4

Other (accompanied by a footnote describing the transaction)